We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-4.34%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$63.9M
(-18%)
Cap. Flow
-$54.5M
Cap. Flow
% of AUM
-18.25%
Top 10 Holdings %
Top 10 Hldgs %
28.29%
Holding
166
New
33
Increased
12
Reduced
17
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PEPLU
PepperLime Health Acquisition Corporation Unit
PEPLU
|
+$7.47M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$5.84M |
| 3 |
DexCom
DXCM
|
+$5.47M |
| 4 |
Karyopharm Therapeutics
KPTI
|
+$5.36M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
+$5.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lantheus
LNTH
|
+$8.71M |
| 2 |
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
|
+$7.2M |
| 3 |
Immatics
IMTX
|
+$6.32M |
| 4 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$6.19M |
| 5 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$5.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.49% |
| 2 | Financials | 7.32% |
| 3 | Industrials | 1.2% |
| 4 | Technology | 0.83% |
| 5 | Communication Services | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Protagonist Therapeutics
PTGX
$8.8B
| $11.8M | 3.96% |
+5,000
| New | +$141K |
|
|
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
| $11.6M | 3.88% |
2,496,524
-19,261
| -0.8% | -$82.6K |
|
|
BLU
3
DELISTED
BELLUS Health Inc.
BLU
| $9.98M | 3.34% |
1,450,006
| – | – |
|
|
4
Protagonist Therapeutics
PTGX
$8.8B
| $9.14M | 3.06% |
386,000
+40,000
| +12% | +$1.13M |
|
|
KDNY
5
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8.92M | 2.98% |
545,000
| – | – |
|
|
PEPLU
6
DELISTED
PepperLime Health Acquisition Corporation Unit
PEPLU
| $7.23M | 2.42% |
+735,000
| New | +$7.47M |
|
7
Keros Therapeutics
KROS
$199M
| $6.85M | 2.29% |
126,000
+10,000
| +9% | +$513K |
|
|
8
DexCom
DXCM
$28.9B
| $6.39M | 2.14% |
+50,000
| New | +$5.47M |
|
9
Insmed
INSM
$22.6B
| $6.3M | 2.11% |
268,000
+64,646
| +32% | +$1.5M |
|
10
QuidelOrtho
QDEL
$1.14B
| $6.3M | 2.11% |
56,000
+19,000
| +51% | +$2.03M |
|
11
ADMA Biologics
ADMA
$2.04B
| $6.04M | 2.02% |
3,300,000
| – | – |
|
12
Globus Medical
GMED
$10.9B
| $5.83M | 1.95% |
79,000
+20,000
| +34% | +$1.39M |
|
|
13
Tandem Diabetes Care
TNDM
$1.22B
| $5.82M | 1.95% |
+50,000
| New | +$5.84M |
|
|
NVRO
14
DELISTED
NEVRO CORP.
NVRO
| $5.57M | 1.86% |
77,000
+35,000
| +83% | +$2.52M |
|
15
Relmada Therapeutics
RLMD
$549M
| $5.56M | 1.86% |
206,000
| – | – |
|
|
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
| $5.44M | 1.82% |
1,750,000
| – | – |
|
17
Glaukos
GKOS
$8.89B
| $5.43M | 1.82% |
94,000
+13,000
| +16% | +$688K |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$275M
| $5.27M | 1.76% |
120,000
-52,000
| -30% | -$2.43M |
|
19
Envista
NVST
$4.39B
| $5.12M | 1.71% |
+105,000
| New | +$4.84M |
|
|
MBTC
20
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $5.04M | 1.69% |
500,000
| – | – |
|
|
SWAV
21
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $4.77M | 1.6% |
+23,000
| New | +$3.79M |
|
|
22
Karyopharm Therapeutics
KPTI
$161M
| $4.75M | 1.59% |
+43,000
| New | +$5.36M |
|
23
Qiagen
QGEN
$8.72B
| $4.56M | 1.53% |
87,704
| – | – |
|
|
RNAM
24
DELISTED
Avidity Biosciences
RNAM
| $4.49M | 1.5% |
243,000
+18,000
| +8% | +$306K |
|
25
Crinetics Pharmaceuticals
CRNX
$8.88B
| $4.48M | 1.5% |
204,000
-127,000
| -38% | -$2.57M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Altium Capital Management held 166 positions worth $299M, down 18% from $363M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Altium Capital Management withdrew a net $54.5M in Q1 2022, closing 48 positions and reducing 17 holdings. Its most notable exit was PepperLime Health Acquisition Corporation Class A Ordinary Share, an estimated $7.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 80% a quarter earlier, followed by Financials and Industrials.
Against the trend, Altium Capital Management opened a new position in PepperLime Health Acquisition Corporation Unit worth $7.23M.
- Altium Capital Management's largest Q1 2022 buy was PepperLime Health Acquisition Corporation Unit: 735,000 shares worth $7.23M.
- Altium Capital Management added most to NEVRO CORP. in Q1 2022, an estimated $2.52M increase.
- Altium Capital Management's biggest Q1 2022 reduction was Lantheus, cutting an estimated $8.71M.
- Altium Capital Management fully exited PepperLime Health Acquisition Corporation Class A Ordinary Share in Q1 2022, selling an estimated $7.2M.
- Altium Capital Management's ten largest holdings make up 28% of its $299M portfolio in Q1 2022.
- Altium Capital Management opened 33 new positions and closed 48 in Q1 2022.
- Altium Capital Management's portfolio value fell 18% quarter-over-quarter to $299M.
Based on Altium Capital Management's 13F filing for Q1 2022, filed 16 May 2022.